Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 6/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 7/20 | 0.39 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30147480 | 1.00 | HCAR3 (0.42) | HCAR3HPGDHCAR2HDAC8EZH2 | |
| SCHEMBL29301509 | 0.86 | CYP2A6 (0.42) | HPGDHDAC8EZH2MAOB | |
| SCHEMBL4133044 | 0.84 | HCAR3 (0.56) | HCAR3HPGDHCAR2HDAC8EZH2 | |
| SCHEMBL30147589 | 0.82 | MAOB (0.45) | HDAC8EZH2MAOB | |
| SCHEMBL30147603 | 0.82 | CYP11B1 (0.47) | HPGDHDAC8EZH2MAOBHSD17B10 | |
| SCHEMBL6840439 | 0.79 | GCGR (0.48) | HCAR3HPGDHCAR2HDAC8HSD17B10 | |
| SCHEMBL15185681 | 0.77 | HCAR3 (0.42) | HCAR3HPGDHCAR2HSD17B10PLA2G4A | |
| SCHEMBL1144709 | 0.76 | MAOB (0.56) | HCAR3HPGDMAOB | |
| SCHEMBL30159516 | 0.76 | MAOB (0.56) | HCAR3HPGDMAOB | |
| SCHEMBL27955207 | 0.76 | HCAR3 (0.41) | HCAR3HPGDHCAR2MAOBHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228504-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-07-11 | — | — | US | disclosed |
| US-20240228504-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-07-11 | — | — | US | disclosed |
| EP-4149945-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | Arbutus Biopharma Corporation (CA) | 2023-03-22 | — | — | EP | disclosed |
| CN-115551864-A | Substituted tricyclic amides, analogs thereof, and methods of using the same | 爱彼特生物制药公司 | 2022-12-30 | — | — | CN | disclosed |
| WO-2021229302-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2021-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228504-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | SLC10A1, NR1H4, SLC10A2 | HCAR3 388/4885HPGD 808/4885HCAR2 279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.